statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recap: GT Biopharma Q4 Earnings

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GT Biopharma trading halted, news pending

GT Biopharma announces 1-for-30 reverse stock split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the Company ), a clinical stage immuno-oncology company focused on developing innovative therapeutics...

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

GT Biopharma, Inc. (NASDAQ:GTBP  Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 58,800...

Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 150.2%

GT Biopharma (NASDAQ:GTBP  Get Free Report) and PaxMedica (NASDAQ:PXMD  Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the...

GT Biopharma (NASDAQ:GTBP) & PaxMedica (NASDAQ:PXMD) Critical Survey

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

GT Biopharma Inc

Volume	2,858.00
52-Wk High	$16.11
52-Wk Low	$2.95

Period	Estimated	Reported	Surprise	Result
Q4'23	-$2.70	--	--	N/A
Q3'23	-$0.09	-$1.80	-2017.65%	MISSED
Q2'23	-$0.10	-$0.06	44.98%	BEAT
Q1'23	-$0.15	-$0.01	93.10%	BEAT
Q4'22	-$0.18	-$0.18	-2.86%	MISSED

GTBP GT Biopharma Inc

About

Feed

News

Earnings

Fundamentals